doi: 10.3389/fnut.2022.1007816 Received 31 July 2022 Accepted 12 October 2022 Published 01 November 2022 Volume 9 - 2022 Edited by Yannan Jin, De Montfort University, United Kingdom Reviewed by Mostafa Waly, Sultan Qaboos University, Oman
Unapproved does not necessarily mean unlawful, but it does mean they have not been assessed for safety, quality and effectiveness by the Therapeutic Goods Administration (TGA)
Based on the available preclinical studies and the vast body of anecdotal data from the research community, a general consensus has started to form around oral BPC-157 dosage
What FDA has said recently (high-level, patient-friendly summary) FDA maintains a page describing certain bulk drug substances used in compounding that may present significant safety risks, including AOD-9604, noting concerns such as potential immunogenicity and limited safety-related information for some uses/routes
Neuroprotection & cognitive function investigations
Semaglutide for diabetes or weight management may be covered
